In vitro evaluation of the activities of telavancin, cefazolin, and vancomycin against methicillin-susceptible and methicillin-resistant Staphylococcus aureus in peritoneal dialysate.
This study compared the ability of telavancin to the ability of cefazolin and vancomycin to eliminate staphylococci from peritoneal dialysis fluid by using a static in vitro model to simulate the conditions of peritoneal dialysis. The results showed that telavancin exhibited statistically significantly better kill (P < 0.05) against both methicillin-susceptible and methicillin-resistant Staphylococcus aureus.
Clouse
Frances L
FL
The University of Minnesota College of Pharmacy, Antibiotic Pharmacodynamic Research Institute, Department of Experimental and Clinical Pharmacology, Minneapolis, MN 55455, USA.
Hovde
Laurie B
LB
Rotschafer
John C
JC
D000617:Aminoglycosides / Q000494:pharmacology*; D000900:Anti-Bacterial Agents / Q000494:pharmacology; D002437:Cefazolin / Q000494:pharmacology*; D015314:Dialysis Solutions; D000077427:Lipoglycopeptides; D008712:Methicillin / Q000494:pharmacology*; D016106:Methicillin Resistance / Q000187:drug effects; D008826:Microbial Sensitivity Tests; D010530:Peritoneal Dialysis; D013211:Staphylococcus aureus / Q000187:drug effects* / Q000254:growth & development; D013997:Time Factors; D014640:Vancomycin / Q000494:pharmacology*
D000617:Aminoglycosides; D000900:Anti-Bacterial Agents; D015314:Dialysis Solutions; D000077427:Lipoglycopeptides; D014640:Vancomycin; D002437:Cefazolin; D008712:Methicillin; C487637:telavancin